{"id":"sd-101-dermal-cream-6","brandName":"SD-101 Dermal Cream (6%)","genericName":"SD-101 Dermal Cream (6%)","companyId":"scioderm-inc","companyName":"Scioderm, Inc.","phase":"phase_3","status":"active","modality":"Small molecule","aliases":["SD-101","SD-101-6.0","Zorblisa"],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"SD-101 Dermal Cream (6%) is a topical treatment under development by Scioderm, Inc. for Epidermolysis Bullosa. It has completed Phase 2 trials and is currently in Phase 3. The cream aims to improve wound healing and reduce pain, with a focus on safety and efficacy.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SD-101 at 6% concentration is being developed by Scioderm, Inc. as a dermatological therapeutic. The specific molecular mechanism and active pharmaceutical ingredient details are not widely available in public literature, limiting detailed mechanistic characterization at this phase of development.","oneSentence":"SD-101 is a topical dermal cream formulation designed to treat skin conditions through a proprietary mechanism not publicly disclosed in detail.","_ai_confidence":"low"},"administration":{},"safety":{"commonSideEffects":[]},"trials":[],"indications":{"approved":[{"name":"Dermatological indication (specific indication not publicly disclosed)"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}